inosine dialdehyde (inox)

01/01/2017 - "The INOX trial will likely determine whether supplemental oxygen during sleep is effective in reducing mortality, delaying the need for LTOT and improving health-related quality of life in patients with COPD who desaturate overnight. "
01/01/2022 - "The study was a secondary analysis of the INOX trial, a 4-year randomised trial of nocturnal oxygen in COPD. "
01/01/2017 - "The primary objective of the International Nocturnal Oxygen (INOX) trial is to determine, in patients with COPD not qualifying for LTOT but who present significant nocturnal arterial oxygen desaturation, whether nocturnal oxygen provided for a period of 3 years decreases mortality or delay the prescription of LTOT. "
01/01/2017 - "Multi-center, randomized, placebo-controlled trial of nocturnal oxygen therapy in chronic obstructive pulmonary disease: a study protocol for the INOX trial."

04/01/1986 - "During a phase I evaluation of diglycoaldehyde (INOX), an intravenous chemotherapeutic agent used to treat children with malignancies, all of eight patients tested developed a positive direct antiglobulin test (DAT) in vivo. "
07/01/1977 - "Mechanism of action of inosine dialdehyde (NSC 118994) in the inhibition of proliferation of tumor cells in culture."
04/01/1980 - "Phase II evaluation of diglycoaldehyde (Inox) in children with acute leukemia: a children's cancer study group report."
07/01/1975 - "Inosine dialdehyde, an antitumor agent highly active against several murine tumors, ispresently undergoing clinical trial for potential activity in man. "
09/01/1976 - "The ribonucleotide reductase activity in cell-free extracts prepared from Ehrlich tumor cells treated with Inox or PI-IMP in culture was decreased compared with the activity in the extracts from untreated cells. "

04/01/1980 - "A phase I trial of diglycoaldehyde (Inox) in children with leukemia established that the maximum tolerated dose of a 5-day schedule was 1.5 g/m2/day. "
04/01/1980 - "Phase II evaluation of diglycoaldehyde (Inox) in children with acute leukemia: a children's cancer study group report."

01/01/2019 - "platensis groups were subjected to partial crush injury at the level of T12 with Inox number 2 modified forceps by compressing on the spinal cord for 30 s. "
01/01/2014 - "A laminectomy was performed at T12 and an Inox No.2 modified forceps was used to perform a partial crush injury on the spinal cord. "

04/01/1980 - "Inox was inactive against advanced acute lymphocytic leukemia."